Optimizing efficacy of Amphotericin B through nanomodification.
about
Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice.Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancerLiposomal resiquimod for the treatment of Leishmania donovani infection.Targeting Hypoxia Inducible Factors-1α As a Novel Therapy in FibrosisBiodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.Biomimetically engineered Amphotericin B nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals.
P2860
Q33947926-9311B6DC-FA0F-40A9-8B1D-2220D6711920Q35168703-0D64FE1C-6372-487D-88D6-2119258D73F5Q36951503-99E4C1D8-805F-4887-A77D-1E901500B14FQ37388288-C64B1B58-9AAE-4406-BE06-F1C513BFEF7EQ39370856-ACCC22E3-F7C6-41A4-89DB-596229D7B407Q40166247-EE7AAEED-E4AA-4532-A093-F77C398BBF7FQ41703512-9C15F70B-C66C-4E73-A8D9-34EA3F768A70
P2860
Optimizing efficacy of Amphotericin B through nanomodification.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Optimizing efficacy of Amphotericin B through nanomodification.
@en
Optimizing efficacy of Amphotericin B through nanomodification.
@nl
type
label
Optimizing efficacy of Amphotericin B through nanomodification.
@en
Optimizing efficacy of Amphotericin B through nanomodification.
@nl
prefLabel
Optimizing efficacy of Amphotericin B through nanomodification.
@en
Optimizing efficacy of Amphotericin B through nanomodification.
@nl
P2860
P921
P1476
Optimizing efficacy of Amphotericin B through nanomodification
@en
P2093
Gillian Barratt
P2860
P304
P407
P577
2007-01-01T00:00:00Z